API Suppliers
US DMFs Filed
CEP/COS Certifications
0
JDMFs Filed
0
Other Certificates
0
Other Suppliers
0
0
USA (Orange Book)
Europe
Canada
Australia
South Africa
Uploaded Dossiers
0
U.S. Medicaid
Annual Reports
Details:
Truvelog Mix 30 is approved and available as a 100 U/ml suspension for injection. The active substance of Truvelog Mix 30 is insulin aspart, an intermediate- or long-acting insulin which is combined with fast-acting insulin and used in diabetes.
Lead Product(s): Insulin aspart
Therapeutic Area: Endocrinology Product Name: Truvelog Mix 30
Highest Development Status: ApprovedProduct Type: Peptide
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 24, 2022
Details:
Under the partnership, USV and Biogenomics launched Insuquick, India's first biosimilar insulin aspart, a rapid-acting analogue of insulin, for the treatment of diabetes.
Lead Product(s): Insulin aspart
Therapeutic Area: Endocrinology Product Name: Insuquick
Highest Development Status: ApprovedProduct Type: Peptide
Partner/Sponsor/Collaborator: Biogenomics
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Partnership November 09, 2023
Details:
Under the terms of the agreement, Meitheal, through its parent company, will receive exclusive rights to commercialize biosimilar versions of insulin aspart, insulin lispro, and insulin glargine in the U.S. upon approval by the FDA.
Lead Product(s): Insulin aspart
Therapeutic Area: Endocrinology Product Name: Undisclosed
Highest Development Status: PreclinicalProduct Type: Peptide
Partner/Sponsor/Collaborator: Meitheal Pharmaceuticals
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Licensing Agreement September 21, 2023
Details:
AT247 is an ultra-rapid insulin that aims to accelerate insulin absorption, post injection, to enable more effective management of blood glucose levels for people living with diabetes, particularly around difficult to manage mealtimes.
Lead Product(s): Insulin aspart
Therapeutic Area: Endocrinology Product Name: AT247
Highest Development Status: Phase IProduct Type: Peptide
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 23, 2022
Details:
The new data pertained to three proposed biosimilar Gan & Lee insulin analogs, insulin aspart (GL-ASP), insulin lispro (GL-LIS), and insulin glargine (GL-GLA), and were presented by the primary investigators from Profil, (Germany).
Lead Product(s): Insulin aspart
Therapeutic Area: Endocrinology Product Name: GL-ASP
Highest Development Status: Phase IProduct Type: Peptide
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 02, 2021
Details:
Kixelle, a fast-acting insulin analog indicated for the treatment of diabetes mellitus in adults, adolescents and children aged 1 year and above, has been approved as a 100 units/ml solution for injection in vial and pre-filled pen presentations.
Lead Product(s): Insulin aspart
Therapeutic Area: Endocrinology Product Name: Kixelle
Highest Development Status: ApprovedProduct Type: Peptide
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 12, 2021
Details:
The biosimilar insulin aspart is currently in development and Lannett will help manage the remaining clinical and regulatory steps specific for a U.S. Food and Drug Administration (FDA) approval to market the product.
Lead Product(s): Insulin aspart
Therapeutic Area: Endocrinology Product Name: Undisclosed
Highest Development Status: UndisclosedProduct Type: Peptide
Partner/Sponsor/Collaborator: Lannett
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration February 09, 2021